Pulmocide recently completed a Phase 2 safety and tolerability clinical trial (OPERA-S study) in lung transplant patients receiving inhaled opelconazole monotherapy as prophylaxis against pulmonary ...

CARGO's tri-specific CAR T, cleared by the FDA; Phase 1 study enrollment expected to initiate mid-year 2025 - - CARGO announces novel allogeneic platform based on a universal allogeneic-enabling ...

Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Aktis Oncology, an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for large patient populations not addressed by existing platform technologies, ...

Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance rangeExciting development-stage pipeline with ...